Rosuvastatin‐Induced Carotid Plaque Regression in Patients With Inflammatory Joint Diseases: The Rosuvastatin in Rheumatoid Arthritis, Ankylosing Spondylitis and Other Inflammatory Joint Diseases Study
暂无分享,去创建一个
Inge Christoffer Olsen | G. Kitas | I. Holme | J. Hisdal | A. Semb | T. Kvien | T. Pedersen | S. Rollefstad | E. Ikdahl | H. Hammer | K. Smerud
[1] Inge Christoffer Olsen,et al. Disease activity and left ventricular structure in patients with rheumatoid arthritis. , 2015, Rheumatology.
[2] L. Punzi,et al. Atherosclerosis progression in psoriatic arthritis patients despite the treatment with tumor necrosis factor-alpha blockers: a two-year prospective observational study. , 2014, Joint, bone, spine : revue du rhumatisme.
[3] T. Naqvi,et al. Carotid intima-media thickness and plaque in cardiovascular risk assessment. , 2014, JACC. Cardiovascular imaging.
[4] I. Holme,et al. Systemic inflammation in patients with inflammatory joint diseases does not influence statin dose needed to obtain LDL cholesterol goal in cardiovascular prevention , 2014, Annals of the rheumatic diseases.
[5] Vijay Nambi,et al. Carotid Plaque or CIMT: What is the Future for Carotid US Imaging? , 2014, Current Cardiovascular Risk Reports.
[6] S. Gabriel,et al. Cardiovascular disease assessment in rheumatoid arthritis: a guide to translating knowledge of cardiovascular risk into clinical practice , 2014, Annals of the rheumatic diseases.
[7] L. Horn,et al. Ethnic Disparities in Cardiovascular Risk Factors in Children and Adolescents , 2014, Current Cardiovascular Risk Reports.
[8] P. Libby,et al. Coronary atheroma volume and cardiovascular events during maximally intensive statin therapy. , 2013, European heart journal.
[9] W. Dixon,et al. Unresolved Questions in Rheumatology: Motion for Debate: The Data Support Evidence-Based Management Recommendations for Cardiovascular Disease in Rheumatoid Arthritis , 2013, Arthritis and rheumatism.
[10] Inge Christoffer Olsen,et al. Carotid Plaque Characteristics and Disease Activity in Rheumatoid Arthritis , 2013, The Journal of Rheumatology.
[11] I. Holme,et al. Treatment to lipid targets in patients with inflammatory joint diseases in a preventive cardio-rheuma clinic , 2012, Annals of the rheumatic diseases.
[12] I. Holme,et al. Effect of intensive lipid-lowering therapy on cardiovascular outcome in patients with and those without inflammatory joint disease. , 2012, Arthritis and rheumatism.
[13] Shah Ebrahim,et al. European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012) , 2012, International Journal of Behavioral Medicine.
[14] Peter Libby,et al. Effect of two intensive statin regimens on progression of coronary disease. , 2011, The New England journal of medicine.
[15] D. O'leary,et al. Carotid atherosclerosis predicts incident acute coronary syndromes in rheumatoid arthritis. , 2011, Arthritis and rheumatism.
[16] M. Quinn,et al. Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. , 2011, Rheumatology.
[17] D. Atar,et al. Remission is the goal for cardiovascular risk management in patients with rheumatoid arthritis: a cross-sectional comparative study , 2011, Annals of the rheumatic diseases.
[18] M. Hochberg,et al. Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis , 2010, Annals of the rheumatic diseases.
[19] M. González-Gay,et al. Insulin resistance in rheumatoid arthritis: the impact of the anti‐TNF‐α therapy , 2010, Annals of the New York Academy of Sciences.
[20] P. Kiely,et al. The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. , 2010, Rheumatology.
[21] G. Kitas,et al. Atherosclerosis in Rheumatoid Arthritis Versus Diabetes: A Comparative Study , 2009, Arteriosclerosis, thrombosis, and vascular biology.
[22] C. Liapis,et al. Aggressive lipid-lowering is more effective than moderate lipid-lowering treatment in carotid plaque stabilization. , 2009, Journal of vascular surgery.
[23] P. Libby,et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. , 2008, The New England journal of medicine.
[24] M. Dougados,et al. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis , 2008, Annals of the rheumatic diseases.
[25] T. Therneau,et al. The widening mortality gap between rheumatoid arthritis patients and the general population. , 2007, Arthritis and rheumatism.
[26] B. Tomlinson,et al. Impact of TNF inhibition on insulin resistance and lipids levels in patients with rheumatoid arthritis , 2007, Clinical Rheumatology.
[27] P. McBride,et al. Ultrasound-detected carotid plaque as a predictor of cardiovascular events , 2006, Vascular medicine.
[28] Richard B Devereux,et al. Preclinical Carotid Atherosclerosis in Patients with Rheumatoid Arthritis , 2006, Annals of Internal Medicine.
[29] O. Faergeman,et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. , 2005, JAMA.
[30] Philip J. Barter,et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. , 2005, The New England journal of medicine.
[31] Sheng Kang,et al. Effects of statin therapy on the progression of carotid atherosclerosis: a systematic review and meta-analysis. , 2004, Atherosclerosis.
[32] A. Smit,et al. Measurement of arterial wall thickness as a surrogate marker for atherosclerosis. , 2004, Circulation.
[33] Paul Schoenhagen,et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. , 2004, JAMA.
[34] M. Trip,et al. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolemia (ASAP): a prospective, randomised, double-blind trial , 2001, The Lancet.
[35] P. Shekelle,et al. How to read radiographs according to the Sharp/van der Heijde method. , 1999 .
[36] C. Zarins,et al. Compensatory enlargement of human atherosclerotic coronary arteries. , 1987, The New England journal of medicine.
[37] R. Levy,et al. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.
[38] B. J. Gersh. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2011 .
[39] A. V. van Gammeren,et al. Analytical performance evaluation of the Cobas 6000 analyzer – special emphasis on trueness verification , 2008, Clinical chemistry and laboratory medicine.
[40] D. M. van der Heijde,et al. How to read radiographs according to the Sharp/van der Heijde method. , 1999, The Journal of rheumatology.
[41] M. Prevoo,et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. , 1995, Arthritis and rheumatism.